Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: EightyEight who wrote (48)	6/25/2000 9:23:00 PM
From: Secret_Agent_Man	Respond to of 539

Illumina, Inc. Available only to Hoover's Online members. See Samples. 9390 Towne Centre Dr., Ste. 200 San Diego, CA 92121 (Map) Phone: 858-587-4290 Fax: 858-587-4297 illumina.com Illumina is here to enlighten. The company is developing instruments that measure genetic variation in individuals to devise new treatments for various diseases. Illumina's main product, the BeadArray, facilitates multiple genetic assays by attaching microscopic beads to fiber-optic bundles; each bead holds a different molecule or DNA sequence. The bundle is then dipped into a test sample, and a laser detects which beads reacted with the sample. Illumina is also developing the Oligator technology, which prepares DNA segments for BeadArray testing. Illumina collaborates with PE Biosystems, Dow Chemical, and Third Wave Technologies. Through the CW Group, director Charles Hartman owns 20% of the company. Top Competitors Luminex \| Sequenom \| Variagenics hoovers.com Variagenics, Inc. Available only to Hoover's Online members. See Samples. 60 Hampshire St. Cambridge, MA 02139 (Map) Destination Guide for Boston, MA Phone: 617-588-5300 Fax: 617-588-5399 variagenics.com Variagenics uses pharmacogenomics, which studies links between genetic variability (measured in single nucleotide polymorphisms, or SNPs) and response to drugs, to develop new drugs and diagnostic products. Products being developed include the Variagenic Impact Program, which analyzes SNP data to identify drug targets, and the NuCleave DNA analysis platform, which performs assays on DNA samples to examine patients' responses to drugs. Initially focused on cancer, the company is now also targeting cardiovascular, neurological, and inflammatory diseases. Variagenics has collaborative agreements with Covance and Quintiles Transnational. The Sprout Group owns more than a fourth of the company, which is going public. Top Competitors Axys Pharmaceuticals \| CuraGen \| Human Genome Sciences hoovers.com

To: EightyEight who wrote (48)	7/4/2000 3:32:46 PM
From: Secret_Agent_Man	Read Replies (1) \| Respond to of 539

llumina sets IPO at 5 mln shares, $9-$11 per share July 3, 2000 05:36 PM Eastern Time WASHINGTON, July 3 (Reuters) - Illumina Inc., a maker of genomics tools for drug research, on Monday set its initial public offering at 5 million shares of common stock in a projected range of $9-$11 per share. It expects to raise $45.2 million in net proceeds from the IPO, an amended prospectus filed with the Securities and Exchange Commission showed. The San Diego-based company plans to use the net proceeds for general corporate development, working capital, funding of operating losses, capital expenditures and potential acquisitions. Illumina develops tools for large-scale analysis of genetic variation and function, which are critical to the development of personalized medicine. It has applied to trade its shares on Nasdaq under the symbol "ILMN" ILMN . Its underwriters, led by Goldman Sachs & Co., have the option of buying 750,000 additional shares in the event of heavy demand, according to the filing. Once the company goes public, there will be about 30.5 million shares outstanding in the company. That would give the company an initial market capitalisation of $335.5 million based on a median price of $10 per share.